Dear Shareholders,
The Board of Directors hereby submits the report of the business and operations of your
Company ("the Company"), along with the audited financial statements, for the
financial year ended March 31, 2023.
1. FINANCIAL HIGHLIGHTS (Rs. In Lakhs)
Particulars |
2022-23 |
2021-22 |
Revenue from Operations |
4,502.73 |
2,471.71 |
Other Income |
157.73 |
72.00 |
Total Revenue |
4,660.46 |
2,543.71 |
Expenses: |
|
|
Cost of materials consumed |
- |
- |
Purchases of Stock-in-Trade |
2,013.69 |
1,270.64 |
Changes in inventories of finished goods work-in-progress and
Stock-in-Trade |
130.23 |
-43.87 |
Employee benefit expenses |
547.01 |
342.35 |
Finance costs |
23.25 |
8.72 |
Depreciation and amortization expenses |
47.73 |
15.48 |
Other expenses |
757.16 |
489.05 |
Total expenses |
3,519.07 |
2,082.37 |
Profit/(Loss) before Tax |
1,141.39 |
461.34 |
Less: Tax Expenses |
|
|
Current Tax |
300.00 |
119.40 |
Tax of earlier years (Net) |
(0.29) |
- |
Deferred Tax liability |
(8.60) |
(1.47) |
Profit for the period |
850.28 |
343.41 |
2. COMPANY'S PERFORMANCE
The total income for the year stood at Rs. 4660.46 lakhs, which is higher by 83.21%
than the previous year's total Income of Rs. 2543.72 lakhs. While the company has earned
the profit of Rs. 850.28 lakhs, which is also higher by 147.60% as compared to the
previous year's Profit of Rs. 343.41 Lakhs.
3. MANAGEMENT DISCUSSION & ANALYSIS
A detailed review of the operations, performance and future outlook of the Company and
its businesses is given in the Management Discussion and Analysis Report which forms part
of this Report as Annexure 1.
4. INITIAL PUBLIC OFFER & LISTING OF SHARES
Your Company got Listing Approval from NSE for Initial Public Issue of 3,88,000 Equity
Shares of face value of Rs. 10/- each at a price of Rs.1229/- on May 26,2023.
The 3,88,000 equity shares of the company were listed on the NSE (EMERGE) Platform on
May 29, 2023.
Your Company has successfully concluded its maiden public issue of equity shares during
the year 2023-24 aggregating to Rs. 4,768.52 lakhs.
5. DIRECTORS AND KEY MANAGERIAL PERSONNEL
In accordance with the requirements of the Act and the Company's Articles of
Association, Ms. Roma Vinodbhai Shah (DIN: 07214632) retires by rotation and being
eligible, offers herself for re-appointment. Relevant resolutions seeking shareholders'
approval forms part of the Notice.
During the year under review, the Non-Executive Directors of the Company had no
pecuniary relationship or transactions with the Company, other than sitting fees and
reimbursement of expenses, if any incurred by them for the purpose of attending meetings
of the Board/Committee of the Company.
Further, during the year 2022-23, the following changes have been made in Board of
Directors of the Company:
Name of Director |
Category Cum Designation |
Appointment/ Change in Designation |
Date of Appointment/ Change in Designation |
Mr. Vishrut Chandramauli Pathak |
Additional Director designated as Independent Director |
Appointment |
January 06,2023 |
Mr. Balwant Purohit |
Additional Director as designated Independent Director |
Appointment |
January 06,2023 |
Ms. Sanjana Sanjeev Shah |
Additional Director designated as Independent Director |
Appointment |
January 06,2023 |
Mr. Arpit Deepakkumar Shah |
Managing Director |
Change in Designation |
January 16, 2023 |
Mr. Swapnil Jatinbhai Shah |
Chairman and Whole Time Director |
Change in Designation |
January 16, 2023 |
Ms. Roma Vinodbhai Shah |
Whole Time Director |
Change in Designation |
January 16, 2023 |
Mrs. Anar Swapnil Shah |
Whole Time Director |
Change in Designation |
January 16, 2023 |
Mr. Vishrut Chandramauli Pathak |
Non- Executive Independent Director |
Change in Designation |
January 21, 2023 |
Mr. Balwant Purohit |
Non- Executive Independent Director |
Change in Designation |
January 21, 2023 |
Ms. Sanjana Sanjeev Shah |
Non- Executive Independent Director |
Change in Designation |
January 21, 2023 |
Pursuant to the provisions of Section 203 of the Act, the Key Managerial Personnel of
the Company as on March 31, 2023 are:
Mr. Arpit Deepakkumar Shah- Managing Director
Mr. Swapnil Jatinbhai Shah - Chairman and Whole Time Director
Ms. Roma Vinodbhai Shah - Whole Time Director
Mrs. Anar Swapnil Shah- Whole Time Director
Ms. Anjali Shah - Chief Financial Officer*
Ms. Deval Patel- Company Secretary and Compliance Officer**
*Ms. Anjali Shah has been appointed as Chief Financial Officer of the Company w.e.f
January 06,2023.
** Ms. Deval Patel has been appointed as Company Secretary and Compliance Officer
w.e.f. January 06, 2023.
As on March 31, 2023 the Board Composition is as follows: -
Name of Director |
DIN |
Category Cum Designation |
Date of Appointment/ Change in Designation |
No. of shares held as on March 31, 2022 |
Mr. Arpit
Deepakkumar
Shah |
07214641 |
Managing Director |
January 16, 2023 |
2,50,000 |
Mr. Swapnil Jatinbhai Shah |
05259821 |
Chairman and Whole Time Director |
January 16, 2023 |
2,50,000 |
Ms. Roma Vinodbhai Shah |
07214632 |
Whole Time Director |
January 16, 2023 |
2,50,000 |
Mrs. Anar Swapnil Shah |
06895297 |
Whole Time Director |
January 16, 2023 |
2,50,000 |
Mr. Vishrut
Chandramauli
Pathak |
03278445 |
Non- Executive Independent
Director |
January 21, 2023 |
Nil |
Mr. Balwant Purohit |
09806032 |
Non- Executive Independent
Director |
January 21, 2023 |
1,000 |
Ms. Sanjana Sanjeev Shah |
09811689 |
Non- Executive Independent
Director |
January 21, 2023 |
Nil |
6. TRANSFER TO GENERAL RESERVE
The Company has not transferred any amount to the general reserve out of the amount
available for appropriation.
7. DIVIDEND
The Board has recommended a final dividend at the rate of 20% of face value of Equity
shares i.e. Rs. 2/- per share for financial year ending March 31,2023, subject to approval
of members at the ensuing AGM. The total dividend pay-out will amount to Rs. 29.46 Lakhs.
The dividend, if approved at the Annual General Meeting (AGM), will be paid to those
members whose name appears in the Company's Register of Members as on the record date of
September 15, 2023, and the dividend pay-out date will within 30 days from date of
declaration. In compliance with the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirement) Regulations, 2015 ("SEBI Listing
Regulations"), the dividend distribution policy of the Company is available on the
Company's website.
8. CHANGE IN NATURE OF BUSINESS:
During the year, the Company has not changed its business or object and continues to be
in the same line of business as per the main object of the Company.
9. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND
The provision of Section 125 does not apply to the Company as the Company has not
declared any dividend prior to the proposed dividend, in any of the earlier financial
years.
10. SHARE CAPITAL
Authorised Capital: -
The Authorized Share Capital of the Company is Rs. 2,00,00,000/- (Rupees Two Crore
Only) divided into 2,00,000 (Two Lakhs) Equity Shares of Rs. 10 each.
During the period under review the members of the Company in the general meeting held
on November 19,2022 had increased the Authorised Share Capital of the Company from Rs.
1,00,00,000/- (Rupees One Crore Only) to Rs. 2,00,00,000/- (Rupees Two Crore Only).
Issued, Subscribed & Paid-Up Capital: -
The issued, subscribed and paid-up capital of the Company is Rs. 1,08,50,000 (One Crore
Eight Lakhs Fifty Thousand only) divided into 10,85,000 (Ten Lakhs Eighty-Five Thousand)
equity shares of Rs. 10 each.
During the period under review, the Paid-up equity capital of the Company increased
from Rs. 1,00,00,000/- to Rs. 1,08,50,000/- pursuant to the issuance of shares on
preferential basis by the Company.
The Company has issued and allotted 85,000(Eighty-Five Thousands) equity shares of INR
10/- each per share, at a premium of INR 490/- each per share, making total of INR 500/-
per share to various investors on December 30,2022 by way of preferential issue.
Further, during the period under review, your Company has not bought back any of its
securities / has not issued any Sweat Equity Shares / has not issued shares with
Differential Voting rights / has not issued any shares under Employee stock option plan
and there has been no change in the voting rights of the shareholders.
Further, after the completion of the financial year and before adoption of Board's
report the Company came out with the Initial Public Offer and hence, issued and allotted
3,88,000 equity shares of Rs. 10 each at the premium of Rs. 1219 per equity share.
Accordingly, paid- up share capital of the Company stood enhanced to Rs. 1,47,30,000. The
Company got listed on the NSE EMERGE platform of National Stock Exchange on May 29,2023.
11. CHANGE IN CONSTITUTION AND NAME OF THE COMPANY
During the period under review, the Company had converted itself from the Private
Limited Company to Public Limited Company and hence the Company was issued new Certificate
of incorporation dated January 06,2023 in the name of Remus Pharmaceuticals Limited.
The members' of the Company in their general meeting held on January 02,2023 have
adopted new Articles of Association and Memorandum of Association pursuant to Conversion
of the Company from Private Limited to Public Limited Company.
12. GENERAL MEETINGS
During the year under review, the following General Meetings were held, the details of
which are given as under:
Sr. No. |
Date of Meeting |
Type of Meeting |
01 |
01.09.2022 |
Extra Ordinary General Meeting |
02 |
30.09.2022 |
Annual General Meeting |
03 |
19.11.2022 |
Extra Ordinary General Meeting |
04 |
05.12.2022 |
Extra Ordinary General Meeting |
05 |
10.12.2022 |
Extra Ordinary General Meeting |
06 |
20.12.2022 |
Extra Ordinary General Meeting |
07 |
02.01.2023 |
Extra Ordinary General Meeting |
08 |
21.01.2023 |
Extra Ordinary General Meeting |
13. DISCLOSURE BY DIRECTORS
The Directors on the Board have submitted notice of interest under Section 184(1) i.e.
in Form MBP 1, intimation under Section 164(2) i.e. in Form DIR 8 and declaration as to
compliance with the Code of Conduct of the Company.
14. CHANGE IN REGISTERED OFFICE
During the year, there was no change in Registered Office of the Company.
15. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE
COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS
RELATE AND THE DATE OF THE REPORT
The material changes and commitments affecting the financial position of the Company
that have occurred between the end of the financial year of the company to which the
financial statements relate and the date of this report is that the company got the
Listing Approval of Draft Red Herring Prospectus (DRHP) for Initial Public Issue of
3,88,000 Equity Shares of face value of Rs. 10/- each on May 26, 2023.
After submission of Red Herring Prospectus (RHP) and Prospectus for Initial Public
Issue, the company received the Final Approval for Listing of Equity shares on NSE
(EMERGE) platform on May 26, 2023.
The Company got listed on NSE EMRGE on May 29, 2023 with listing price of Rs. 1711.25/-
per equity share against the issue price of Rs. 1229/- per equity share.
DETAILS OF THE ISSUE OF EQUITY SHARES THROUGH IPO
Equity Shares Offered through Public Issue |
3,88,000 Equity Shares aggregating up to Rs. 4768.52 lakhs |
Out of which: |
|
Issue Reserved for the Market Makers |
19,500 Equity Shares aggregating up to Rs. 239.66 lakhs |
Net Issue to the Public |
3,68,500 Equity Shares aggregating up to Rs. 4528.87 lakhs |
Out of which |
|
A. QIB Portion |
Not more than 1,84,200 Equity Shares aggregating up to Rs. 2263.82
lakhs |
Of which |
|
Anchor Investor Portion |
1,10,500 Equity Shares aggregating up to Rs. 1358.05 lakhs |
Net QIB Portion |
73,700 Equity Shares aggregating up to Rs. 905.77 lakhs |
B. Non- Retail Portion |
Not less than 55,300 Equity Shares aggregating up to Rs. 679.64 lakhs |
C. Retail Portion |
Not less than 1,29,000 Equity Shares aggregating up to Rs. 1585.41
lakhs |
16. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO
A. CONSERVATION OF ENERGY:
(i) The steps taken or impact on the conservation of energy; |
There were no major steps taken for conservation of energy during the
year |
(ii) The steps taken by the company for utilizing alternate sources of
energy; |
Nil |
The capital investment on energy
( conservation equipment; ^
B. TECHNOLOGY ABSORPTION:
(i) |
The efforts made towards technology absorption; |
The Company has not taken any technology in particular or entered into
any technology agreement during the period. During the year, no further development is
done for research |
(ii) |
The Benefits derived like product improvement, cost reduction, product
development or import substitution; |
Nil |
(iii) |
In case of imported technology (imported during the last 5 years
reckoned from the beginning of financial year) - |
No foreign technology is involved. |
|
a) The details of technology imported; |
Nil |
|
b) The year of Import; |
Nil |
|
c) Whether the technology been fully absorbed |
Nil |
|
d) If not fully absorbed, areas where absorption has not taken place,
and reasons there of; and |
Nil |
(iv) |
The expenditure incurred on research and development. |
Nil |
C. FOREIGN EXCHANGE EARNINGS AND OUTGO:
The foreign exchange earned in terms of actual inflows during the year and the foreign
exchange outgo during the year in terms of actual outflows:
Particulars |
Current Year (Amount in Lakhs) |
A) Foreign Exchange Earning |
4395.41 |
B) Foreign Exchange Outgo |
|
1. CIF Value of Capital Goods |
|
2. CIF Value of inputs |
|
3. Other |
178.16 |
17. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF
THE COMPANY
The Company has been taking proactive approach concerning the development and
implementation of a Risk Management Policy after identifying the following elements of
risks which in the opinion of the Board may threaten the very existence of the Company
itself.
(a) financial; (b) legal and regulatory;(c) operating; and(d) commercial risks,
including health, safety and environment.
The Company does not have any Risk Management Committee as the Board takes into
consideration all the risk factors at regular intervals.
18. CORPORATE SOCIAL RESPONSIBILITY
Provisions relating to Corporate Social Responsibility under Section 135 of the
Companies Act, 2013 are not applicable to the Company.
19. INSURANCE
The Company has a broad-banded approach towards insurance. Adequate cover has been
taken for all movable and immovable assets against numerous risks and hazards.
20. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION,
PROHIBITION AND REDRESSAL) ACT, 2013.
Your Company has always believed in providing a safe and harassment free workplace for
every women employee working with your Company. Your Company always endeavours to create
and provide an environment that is free from discrimination and harassment including
sexual harassment.
Your Company has a zero tolerance for sexual harassment at workplace and, therefore,
has in place a policy on prevention of sexual harassment at workplace. The said policy is
in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013 and the Rules thereunder. There was no complaint
outstanding / received from any employee during the financial year 2022-23 and hence, no
complaint is pending as on March 31, 2023 for redressal.
21. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER INSOLVENCY AND
BANKRUPTCY CODE, 2016
During the year under Review, neither any application was made nor any proceedings were
pending under Insolvency and Bankruptcy Code, 2016.
22. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF
ONE-TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL
INSTITUTIONS ALONG WITH THE REASONS THEREOF
Not Applicable
23. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS MADE UNDER SECTION 186 OF THE
COMPANIES ACT, 2013
Loans, Guarantees and Investments covered under Section 186 of the Companies Act, 2013
form part of the notes to the Financial Statements.
During the period under review, the members of the Company in their meeting held on
December 10 ,2022 increased the limits under section 185 and 186 from Rs. 25 Crore, up to
an amount of Rs. 100 crore. Further, the limits under section 185 and 186 were further
increased from Rs. 100 crores up to Rs. 200 crores by the members of the Company in their
meeting held on December 20,2022.
24. DETAILS OF SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS
There are no significant material orders passed by the Regulators / Courts which would
impact the going concern status of the Company and its future operations.
25. MAINTENANCE OF COST RECORDS AND COST AUDIT
Maintenance of Cost Records has been specified by the Central Government, under sub -
section (1) of section 148, of the Companies Act, 2013, and records in not applicable to
the Company.
26. COMPANY'S POLICY RELATING TO DIRECTORS' APPOINTMENT, PAYMENT OF REMUNERATION AND
DISCHARGE OF THEIR DUTIES
The Company's policy on Directors' appointment and remuneration and other matters
provided in Section 178(3) of the Companies Act, 2013 is available on the website of the
Company.
27. FORMAL ANNUAL EVALUATION
As per the provisions of Companies Act, 2013, every listed company and every other
public company having a paid up share capital of twenty five crore rupees or more
calculated at the end of the preceding financial year shall include, in the report by its
Board of directors, a statement indicating the manner in which formal annual evaluation
has been made by the Board of its own performance and that of its committees and
individual directors.
During the year under review the company was neither the listed entity nor had the
paid- up share capital of twenty-five crore rupees or more and hence the said provisions
were not applicable to your company.
28. STATUTORY AUDITORS
The Company has appointed M/s. Parikh & Majmudar, Chartered Accountants (FRN-
107525W) Ahmedabad for a period of Five years from the conclusion of 5th Annual
General Meeting till the conclusion of the 10th Annual General Meeting to conduct Audit
from Financial year 2019-2020 to year 2023-2024. So, there will be no re-appointment of
Auditors at the ensuing AGM of the Company.
The notes forming part of the accounts are self-explanatory as far as Auditor's Report
is concerned and therefore, it does not require any further comments.
29. SECRETARIAL AUDIT REPORT
Pursuant to the provisions of Section 204 of the Act read with The Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014, your Company was not
falling under criteria of Secretarial Audit for FY 2022- 23.
30. ANNUAL RETURN
In compliance with Section 92(3) and 134(3)(a) of the Act, Annual Return is uploaded on
Company's website.
31. DISCLOSURE UNDER RULE-5 OF THE COMPANIES (APPOINTMENT AND REMUNERATION) RULES, 2014
Disclosure required under Section 197 of the Companies Act, 2013 read with Rule-5 of
the Companies (Appointment and remuneration) Rules, 2014 have been annexed as Annexure- 2.
32. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES
The particulars of contracts or arrangements with related parties referred to in
subsection (1) of Section 188 of the Act in Form AOC-2 are annexed herewith as ANNEXURE: 3
to this report.
33. CORPORATE GOVERNANCE
As per regulation 15(2) of the Listing Regulation, the Compliance with the Corporate
Governance provisions shall not apply in respect of the following class of the Companies:
a. Listed entity having paid up equity share capital not exceeding Rs. 10 Crore and Net
worth not exceeding Rs. 25 Crore, as on the last day of the previous financial year;
b. Listed entity which has listed its specified securities on the SME Exchange.
Since, our Company falls in the ambit of aforesaid exemption (b); hence compliance with
the provisions of Corporate Governance shall not apply to the Company and it does not form
the part of the Annual Report for the financial year 2022-23.
34. NUMBER OF BOARD MEETINGS CONDUCTED DURING THE YEAR UNDER REVIEW
The Board of the Company regularly meets to discuss various Business opportunities.
Additional Board meetings are convened, as and when required to discuss and decide on
various business policies, strategies and other businesses.
The Company had Seventeen Board meetings during the financial year under review on:
Sr. No. Date of Meeting |
Sr. No. |
Date of Meeting |
1 27.05.2022 |
10 |
10.12.2022 |
2 30.07.2022 |
11 |
14.12.2022 |
3 05.09.2022 |
12 |
19.12.2022 |
4 06.09.2022 |
13 |
30.12.2022 |
5 27.10.2022 |
14 |
06.01.2023 |
6 10.11.2022 |
15 |
16.01.2023 |
7 18.11.2022 |
16 |
15.02.2023 |
8 24.11.2022 |
17 |
07.03.2023 |
9 01.12.2022 |
|
35. COMMITTEES OF THE BOARD
SR.NO. |
TYPE OF COMMITTEE |
NAME OF MEMBERS |
CHAIRPERSON/ MEMBER |
NATURE OF DIRECTORSHIP |
|
|
|
|
|
1. |
Audit Committee (w.e.f from 16.01.2023) |
Mr. Vishrut Chandramauli
Pathak |
Chairperson |
Independent Director |
Mr. Balwant Purohit |
Member |
Independent Director |
Ms. Sanjana Sanjeev Shah |
Member |
Independent Director |
Mr. Arpit Deepakkumar Shah |
Member |
Managing Director |
Mr. Swapnil Jatinbhai Shah |
Member |
Whole Time Director |
|
|
|
|
|
2. |
Nomination & Remuneration Committee (w.e.f from
16.01.2023) |
Ms. Sanjana Sanjeev Shah |
Chairperson |
Independent Director |
Mr. Vishrut Chandramauli
Pathak |
Member |
Independent Director |
Mr. Balwant Purohit |
Member |
Independent Director |
|
|
|
|
|
3. |
Stakeholders' Relationship Committee (w.e.f from
16.01.2023) |
Mr. Balwant Purohit |
Chairperson |
Independent Director |
Mr. Arpit Deepakkumar Shah |
Member |
Managing Director |
Mr. Swapnil Jatinbhai Shah |
Member |
Whole Time Director |
|
|
|
|
|
4. |
Corporate Social |
Mr. Arpit Deepakkumar Shah |
Chairperson |
Managing Director |
|
Responsibility Committee (w.e.f. 01st May,2023) |
Mr. Swapnil Jatinbhai Shah |
Member |
Whole Time Director |
Ms. Roma Vinodbhai Shah |
Member |
Whole Time Director |
Mr. Balwant Purohit |
Member |
Independent Director |
36. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES
The Company does not have any Subsidiary, Joint venture or Associate Company.
37. INTERNAL AUDITOR
During the period under review, the provisions relating to appointment of Internal
Auditors were not applicable to the Company.
38. INTERNAL CONTROL SYSTEMS & THEIR ADEQUACY
Internal controls encompass a set of rules, policies and procedures to provide
reasonable assurance for achievement of the organizational objectives in operational
effectiveness and efficiency, reliable financial reporting and compliance with laws,
regulations and policies. Your Company's internal control systems are commensurate with
the size and nature of its operations, which records transactions and operations; ensures
protection against misuse or loss of the Company's assets; ensures efficiency in
operations of the plant and facilitates transparency and accuracy of financial reporting.
39. DEPOSITS
The Company has not invited deposit from members or public.
40. WEBSITE
The corporate website is https://remuspharma.com/ reflecting the details and business
of the company. Also, the website displays financial & corporate information.
41. DECLARATION OF INDEPENDENT DIRECTORS
The Company has received the necessary declaration from each Independent Director in
accordance with Section 149(7) of the Act and Regulations 16(1) (b) and 25(8) of the SEBI
Listing Regulations, that he/she meets the criteria of independence as laid out in Section
149(6) of the Act and Regulations 16(1)(b) of the SEBI Listing Regulations. In the opinion
of the Board, there has been no change in the circumstances which may affect their status
as Independent Directors of the Company and the Board is satisfied of the integrity,
expertise, and experience (including proficiency in terms of Section 150(1) of the Act and
applicable rules thereunder) of all Independent Directors on the Board.
Further, in terms of Section 150 read with Rule 6 of the Companies (Appointment and
Qualification of Directors) Rules, 2014, as amended, Independent Directors of the Company
have included their names in the data bank of Independent Directors maintained with the
Indian Institute of Corporate Affairs.
The Board of directors of the Company has taken on record the declaration and
confirmation submitted by the independent directors after undertaking due assessment of
the veracity of the same. There has been no change in the circumstances affecting their
status as Independent Directors of the Company.
42. REPORTING FRAUD
The Auditors of the Company have not reported any fraud as specified under Section
143(12) of the Companies Act, 2013.
43. DIRECTORS RESPONSIBILITY STATEMENT
In accordance with the provisions of Section 134(5) of the Companies Act, 2013 the
Board hereby submit its responsibility Statement:-
(a) in the preparation of the annual accounts, the applicable accounting standards had
been followed along with proper explanation relating to material departures;
(b) the directors had selected such accounting policies and applied them consistently
and made judgments and estimates that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the company at the end of the financial year and of
the profit and loss of the company for that period;
(c) the directors had taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of this Act for safeguarding the
assets of the company and for preventing and detecting fraud and other irregularities;
(d) the directors had prepared the annual accounts on a going concern basis; and
(e) the directors had laid down internal financial controls to be followed by the
company and that such internal financial controls are adequate and were operating
effectively. Internal financial control means the policies and procedures adopted by the
Company for ensuring the orderly and efficient conduct of its business including adherence
to Company's policies, the safeguarding of its assets, the prevention and detection of
frauds and errors, the accuracy and completeness of the accounting records and the timely
preparation of reliable financial information.
(f) the directors had devised proper systems to ensure compliance with the provisions
of all applicable laws and that such systems were adequate and operating effectively.
44. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS
During the year under review, there were no frauds reported by the Company or fraud on
the Company by the officers and employees of the Company has been noticed or reported or
no fraud are reported by the auditors to the Audit Committee or the Board under section
143(12) of the Companies Act, 2013.
45. SECRETARIAL STANDARDS OF ICSI
Your company has complied with the provisions of Secretarial Standards issued by
Institute of Company Secretaries of India.
46. VIGIL MECHANISM/ WHISTLE BLOWER POLICY
The Company has adopted the whistle blower mechanism for directors and employees to
report concerns about unethical behavior, actual or suspected fraud, or violation of the
Company's code of conduct and ethics. The Company has a " VIGIL MECHANISM / WHISTLE
BLOWER POLICY", the copy of which is available on the website of the Company, namely
https: //remuspharma.com/
47. SAFETY & ENVIRONMENT
The Company is committed to providing a safe and healthy working environment and
achieving an injury and illness free work place.
48. GREEN INITIATIVES
In commitment to keep in line with the Green Initiatives and going beyond it,
electronic copy of the Notice of 8th Annual General Meeting of the Company including the
Annual Report for Financial Year 2022-23 are being sent to all Members whose e-mail
addresses are registered with the Company/ Depository Participant(s).
49. ACKNOWLEDGEMENTS
We thank our customers, vendors, dealers, investors, business associates and bankers
for their continued support during the year. We place on record our appreciation of the
contribution made by employees at all levels. Our resilience to meet challenges was made
possible by their hard work, solidarity, cooperation and support.
Place: Ahmedabad |
For and on Behalf of Board of Directors |
Date: August 04,2023 |
Remus Pharmaceuticals Limited |
Sd/- |
Sd/- |
Mr.Swapnil Jatinbhai Shah |
Ms.Roma Vinodbhai Shah |
Chairman and Whole Time Director |
Whole Time Director |
DIN:07214632 |
DIN:05259821 |
|
|